Search results
Wegovy & other GLP-1 drugs to get coverage under Medicare Part D
AARP· 5 hours agoThe FDA recently approved a new use for Wegovy (semaglutide), the blockbuster anti-obesity drug, to reduce the risk of heart attacks and stroke in people with cardiovascular disease who are ...
CVS stock plunges after earnings numbers one analyst 'did not even believe'
Yahoo Finance· 3 hours agoMargins over membership In order to right-size its balance sheet in the face of more Medicare...
As Medicare Part D grows, so does need for fraud audits
BenefitsPRO· 6 days agoCMS is required to audit the financial records of at least one-third of Part D plan sponsors...
A ‘slap in the face’: Retired state workers in Maryland outraged by drug plan switch
Baltimore Sun· 11 hours agoInstead, Varner — a professor emeritus at the University of Maryland, College Park, who was...
Can you Change Your Medicare Plan Outside of Open Enrollment?
TMJ4 Milwaukee· 5 hours agoBen DeGracie is back from Sovereign Select to chat about special circumstances for those on Medicare...
Pfizer stock gains 7% after earnings beat, company calls dividend 'secure'
Yahoo Finance via AOL· 42 minutes agoEliquis represents nearly 14% of Pfizer’s Q1 revenue, and we recognize the uncertainty tied to the...
CMS Advises Preparatory Steps for Anticipated PrEP Coverage Transition to Medicare Part B
The National Law Review· 6 days agoOn April 15, the Centers for Medicare & Medicaid Services (CMS) released a
What is the Medicare Donut Hole and What Are Your Options?
Penny Hoarder via AOL· 4 days agoMedicare can feel complicated. It’s easy to get overwhelmed when sorting through pages of...
CVS Health (CVS) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 4 hours agoWe will provide updates throughout the year on these efforts. I also feel it is important to discuss our long-term outlook for Medicare Advantage. We...
Exelixis Inc (EXEL) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
GuruFocus.com via Yahoo Finance· 13 hours agoCABOMETYX Net Product Revenues: $376.4 million, including about $6 million in clinical trial sales. Gross to Net Deductions: 32.9% for Q1 2024, primarily due to higher Medicare</ ...
